BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Expands bioprocessing footprint across Asia
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
